Targets › HAVCR2
9 programs from 9 companies in 16 trials: 10 Phase 1, 6 Phase 2; Oncology; next expected readout Dec 2026.
Cell surface receptor implicated in modulating innate and adaptive immune responses. Generally accepted to have an inhibiting function. (UniProt, Q8TDQ0)
Open in Phaseline: the race on HAVCR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| GSK | Cobolimab Hepatitis A virus cellular receptor 2 inhibitor | HAVCR2 | Phase 2 | Lung Cancer, Non-Small Cell; Melanoma; Neoplasms; Cervical Cancer … | Dec 2026 |
| University of Washington | Verzistobart TIM-3 inhibitor monoclonal antibody | HAVCR2 | Phase 2 | Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8 | Jan 2027 |
| Novartis | Sabatolimab (MBG453) Hepatitis A virus cellular receptor 2 inhibitor | HAVCR2 | Phase 2 | Myelodysplastic Syndromes | Feb 2028 |
| L & L Bio Co., Ltd., Ningbo, China | LB1410 anti-PD-1 and anti-TIM-3 bispecific antibody | PDCD1, HAVCR2 | Phase 1 | Solid Tumor | Dec 2026 |
| Xuzhou Medical University | anti Tim-3/CD123 CAR-T cell therapy Dual-targeted CAR-T cell therapy targeting Tim-3 and CD123 | HAVCR2, CD123 | Phase 1 | Acute Myeloid Leukemia Refractory | Jan 2027 |
| Tesaro | Cobolimab (TSR-022) Hepatitis A virus cellular receptor 2 inhibitor | HAVCR2 | Phase 1 | Neoplasms | Mar 2027 |
| Servier Bio-Innovation | S095018 Anti-TIM3 antibody | HAVCR2 | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Apr 2027 |
| AstraZeneca | AZD7789 (sabestomig) anti-PD-1 and anti-TIM-3 bispecific antibody | PDCD1, HAVCR2 | Phase 1 | Carcinoma, Non-Small-Cell Lung; Advanced or Metastatic NSCLC | May 2027 |
| Merck & Co. (MSD) | Boserolimab TIM-3 inhibitor | HAVCR2 | Phase 1 | Carcinoma, Non-Small-Cell Lung | Feb 2032 |
Solid Tumor (2) Neoplasms (2) Carcinoma, Non-Small-Cell Lung (2) Myelodysplastic Syndromes (1) Lung Cancer, Non-Small Cell (1) Melanoma (1) Cervical Cancer (1) Adult Primary Liver Cancer (1) Melanoma Stage III (1) Non-small Cell Lung Cancer (NSCLC) (1) Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8 (1) Acute Myeloid Leukemia Refractory (1)
mixed (5), antibody (2), small molecule (1), other (1)
L & L Bio Co., Ltd., Ningbo, China (1) Novartis (1) GSK (1) Merck & Co. (MSD) (1) Servier Bio-Innovation (1) University of Washington (1) Xuzhou Medical University (1) AstraZeneca (1) Tesaro (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.